We have noted previously that duration of vecuronium block correlated with fibre size in six muscle groups in the goat. Electrophysiological considerations suggest that the important factor should be the number of acetylcholine receptors (AChR) relative to fibre size. However, this hypothesis could not be verified in the goat because the number of AChR was relatively constant in the different muscles despite differences in fibre size. Therefore, in this study, we have investigated the relationship between sensitivity to vecuronium, as reflected by the ED 50 and duration of block, of six muscles in the cat and the number of AChR per unit fibre crosssectional area (CSA). The ED 50 and duration of action (time to 50% recovery of the first twitch after a dose of 15 µg kg -1 ) of vecuronium in the tibialis cranialis, soleus, rectus abdominis, masseter, diaphragm and thyroarytenoideus muscles were determined during train-of-four stimulation and EMG recording in seven cats anaesthetized with pentobarbital. CSA of the muscle fibres and number of junctional AChR in these muscles were measured by histological methods and 125 I-α-bungarotoxin binding assay, respectively, and the number of AChR per unit fibre CSA calculated. The association between muscle response (ED 50 and duration of block) and fibre CSA or number of AChR per unit fibre CSA was then tested by regression analyses. Duration of block varied between the six muscles (mean 8.9 (SEM 2.6) to 20.3 (3.1) min; Pϭ0.0001) but ED 50 did not (7.5 (1.5) to 15.6 (2.5) µg kg -1 ; Pϭ0.185). Fibre CSA and number of AChR per unit fibre CSA also varied between these muscles (Pϭ0.0001). Duration to 50% T1 recovery was prolonged in muscles with a low number of AChR relative to fibre CSA (r 2 ϭ0.30; Pϭ0.0002) and the ED 50 increased as the number of AChR per fibre CSA increased (r 2 ϭ0.240; Pϭ0.0016). These results in the cat suggest that the number of junctional AChR relative to fibre CSA is a morphological predictor of the differential sensitivities of muscles to neuromuscular blocking agents.
muscles with large fibres or small end-plates relative to muscle fibre CSA. Electrophysiological considerations suggest that the critical factor that determines the sensitivity of a particular end-plate to the effect of neuromuscular blocking drugs is the amplitude of the end-plate potential which, in turn, is related directly to end-plate current and inversely related to the capacitance of the muscle fibre. The end-plate current, in turn, is related directly to the number of AChR channels opened by acetylcholine, and fibre capacitance is proportional to fibre size. 3 Thus sensitivity to neuromuscular blocking drugs should be large if the number of AChR per end-plate is small and/or if muscle fibre size is large.
The results obtained in the goat are consistent with these predictions. Fibre size differed markedly between muscles of the larynx, abdominal wall, diaphragm and limbs, and muscles composed of large fibres were found to be more sensitive to vecuronium. 1 2 4 However, the role played by the number of AChR could not be assessed because the latter was relatively constant across muscles. To test the hypothesis that sensitivity to neuromuscular blocking drugs is related inversely to the ratio of AChR to fibre CSA, a species in which both receptor number and fibre size vary across muscles is required.
Therefore, in this study, the cat was chosen to investigate if the relationships observed in the goat between duration of block and fibre CSA or relative end-plate size 1 4 applied also in the cat, a species in which fibre size, relative endplate size and number of AChR vary between muscles. Furthermore, we also assessed if the number of junctional AChR per unit fibre CSA, which theoretically should be proportional to the amplitude of the end-plate potential, is a predictor of the differential responses of muscles to neuromuscular blocking drugs.
Materials and methods
After obtaining institutional approval, seven adult cats of both sexes, weighing 2.3-4.5 kg, were used to study vecuronium (Norcuron, Organon Canada, West Hill, Ontario, Canada). The cats were anaesthetized with pentobarbital 40 mg kg -1 i.p., the trachea intubated and mechanical ventilation instituted with air to maintain end-tidal carbon dioxide partial pressure (PEЈ CO 2 ) at 4.4-4.9 kPa (Ohmeda 5200 CO 2 Monitor, BOC Health Care, USA). Anaesthesia was maintained with intermittent i.v. doses of pentobarbital 6-9 mg kg -1 . The femoral artery was cannulated for monitoring arterial pressure and the femoral vein for administration of drugs and fluid. Rectal temperature was maintained at 37-38°C with heating lamps, and together with PEЈ CO 2 , heart rate and arterial pressure (Models 78203A and 78205B, Hewlett-Packard, USA) were monitored continuously and maintained within the physiological range. 5 
Surgical preparation
Under anaesthesia, the evoked electromyogram (EMG) was measured in the masseter, diaphragm, thyroarytenoideus, 285 rectus abdominis, tibialis cranialis and soleus muscles during supramaximal stimulation of their exposed motor nerve supplies. The recurrent laryngeal nerve was exposed midway between the larynx and thoracic inlet, the phrenic nerve within the thoracic cavity through an eighth or ninth intercostal space thoracotomy, the sciatic nerve at the level of the thigh and the 10th intercostal nerve in the dorsal third of the rib cage. The mandibular branch of the fifth cranial nerve to the masseter was stimulated using needle electrodes inserted over the edge of the zygomatic arch and directed caudomedially towards the oval foramen. The evoked EMG response was monitored with bipolar fine wire electrodes (Cooner Wire Company, Chatsworth, CA, USA) inserted into the surgically exposed muscles using hypodermic needles, as described previously. 6 7 Inter-electrode distance was approximately 1 cm for the diaphragm, abdominal and limb muscles, and approximately 5 mm for the masseter and laryngeal muscles. The temperature of muscles of the limb was estimated using a subcutaneous thermistor probe (Model YSI 6394, Temp Medical Products Inc., FL, USA) placed over the gastrocnemius muscle, and was maintained within 1°C of rectal temperature using heating lamps. The stimulating and recording electrodes were designed such that their active surface made contact only with the nerve or muscle under study. All surgical incisions were covered with wet swabs to maintain the vitality of the tissues.
Pharmacodynamic studies
The pair of electrodes from each muscle were connected to a Grass polygraph DC Amplifier Model 7DA via a wide band AC Preamplifier and Integrator Model 7P3 (Grass Instrument Co., MA, USA). The recurrent laryngeal, phrenic, intercostal and sciatic nerves were stimulated with S88 Grass Square pulse stimulators and SIU5 stimulus isolation units, and the mandibular nerve with a hand-held stimulator (DIGISTIM 3PLUS, Neuro Technology, TX, USA). Supramaximal stimuli of 0.2-ms duration were applied simultaneously at 2 Hz for 2 s (train-of-four pattern) every 12 s. The evoked EMG response was confirmed to be biphasic using an oscilloscope, and was then wide-band filtered (0.15 Hz-3 KHz), full-wave rectified and integrated, and the output recorded on a Grass polygraph Model 7S1225.
After obtaining stable baseline records from each muscle, dose-response curves of vecuronium were measured using the 'repeated bolus dose-response' method. The latter was carried out in two phases to study the six muscles using the four-channel Polygraph available. In the first phase, the tibialis cranialis, masseter, soleus and rectus abdominis were studied while in the second phase the tibialis cranialis, thyroarytenoideus, diaphragm and soleus were studied so that the tibialis and soleus muscles served as 'controls' for both phases. The 'repeated bolus dose-response' method used in this study involved injecting a dose of the drug as an i.v. bolus, recording the maximum block produced, allowing the evoked first (T1) and fourth (T4) responses in the train-of-four to recover spontaneously to control levels and another 1.5-2 h to elapse, and then testing the effects of another dose of the same drug in the same animal. Four test doses (range 2.5-20 µg kg -1 ), starting with a dose of 15 µg kg -1 , were studied in each cat. The second batch of muscles was studied similarly. The study lasted 6-10 h in each cat.
Muscle histological studies
At the end of the pharmacodynamic studies, muscle specimens that included the motor end-plate region were obtained from the six muscles and frozen rapidly in isopentane precooled to its freezing point in liquid nitrogen, and stored at -80°C for further studies. Serial transverse sections (10 µm thick) were cut in a cryostat at -25°C and stained for myosin adenosine triphosphatase (mATPase) after preincubation at pH 9.4, 4.5 and 4.3. Fibres were classified into type I (slow-twitch) or II (fast-twitch) on the basis of their weak or strong mATPase activity at pH 9.4, respectively. 8 Under camera-lucida microscopy, approximately 1000 fibres per section were differentially counted and the population of each fibre type expressed as a percentage of the total. The cross-sectional areas (CSA µm 2 ) of 100-200 of each fibre type was measured by computerized planimetry (JAVA, Jandel Scientific, USA). To ensure that the results were accurate and representative of the muscle, the entire section was scanned in a zigzag manner and only transversely cut fibres in 6-10 randomly selected fields were measured.
AChR quantification
The number of AChR at the neuromuscular junction was estimated by 125 I-α-bungarotoxin (αBTX) binding studies on single muscle fibres, as described previously. 9 Briefly, thin strips cut along the muscle length were incubated at room temperature for 90 min in Krebs-Ringer solution containing 125 I-αBTX 1.0 µg ml -1 (approximately 15 µCi µg -1 ) (Du Pont, Canada), rinsed thoroughly in several changes of Krebs-Ringer solution, fixed for approximately 6 h in 4% glutaraldehyde in Millonig buffer (sodium phosphate monobasic 0.12 mol litre -1 , sodium hydroxide 0.07 mol litre -1 and glucose 5 g litre -1 ), and dissociated into single fibres using a Polytron homogenizer (Brinkman PCU-11, probe PT 10/35). 9 The dissociated fibres were incubated at 37°C for 90 min in an acetylthiocholine iodide medium to stain the motor end-plates. 10 After several washes in the buffer, the dissociated fibres were examined under a dissecting microscope (Bausch and Lomb), at ϫ30 magnification, and each fibre with an end-plate was cut into pairs of segments of identical length (approximately 500 µm), and sorted into segments bearing (junctional) or not bearing (extra-junctional) end-plates. The amount of radioactivity bound to a known number (usually 30-50) of junctional and extra-junctional segments was quantified separately by gamma spectrometry (1272 Clinigamma, LKB Wallac, Finland). The number of αBTX molecules corresponding to one count per minute was estimated from a curve relating the number of counts per minute (corrected for counter efficiency) produced by a known quantity of 125 I-αBTX (2.5ϫ10 -4 µg to 7.5ϫ10 -2 µg): one count per minute corresponded to approximately 2.54ϫ10 6 αBTX molecules. The difference in radioactivity between junctional and extrajunctional segments was used to calculate the number of αBTX binding sites per end-plate. 11 The fibre segments were then mounted on microscope slides with an aqueous mountant (Farrant's Medium, BDH Inc). Under cameralucida microscopy, the smallest smooth perimeter around all end-plates presented en face was traced to obtain the end-plate surface area (ESA). The measured ESA was not corrected for fibre surface concavity. 9 The number of αBTX binding sites per end-plate was divided by the mean ESA for the muscle to obtain the mean density of AChR at the end-plate.
Data collection and statistical analyses
From records of the effects of the initial dose of vecuronium 15 µg kg -1 , onset time (time from injection to maximum T1 depression), duration of effect (time from maximum block to 50% T1 recovery) and train-of-four ratio (T4/T1) at 50% T1 recovery were determined. Where maximum block was less than 50%, duration of block was taken as zero. The dose-response curve of vecuronium in each muscle in each cat was constructed by linear regression of the logit transformation of percentage depression of T1 vs the logarithm of the dose. With the exception of the masseter, the dose-response curve in each muscle was constructed from 3-4 points. In three cats, only two points were used to construct the dose-response curve in the masseter because the other doses produced 100% block. The ED 50 (µg kg -1 ) of vecuronium in each muscle in each cat was obtained separately from the individual doseresponse curves. Mean (SEM) onset time, duration of block, T4/T1 at 50% T1 recovery and ED 50 of vecuronium were calculated for each muscle. The ED 50 values of vecuronium in the tibialis and soleus muscles during the two phases were compared to determine if the responses of the muscles studied in the second phase were influenced by drug cumulation. The results suggested some degree of drug cumulation ( Table  1) . Because of this and the marked variability in response between animals, for comparison of ED 50 and duration of block between muscles, values for each muscle were normalized to those in the tibialis muscle in the same cat and phase, and the normalized values compared by one- 
Results

Muscle sensitivity to vecuronium
The responses of the six muscles after the initial dose of vecuronium 15 µg kg -1 are summarized in Table 2 . Onset time for maximum T1 depression ranged from 2.9 (SEM 0.4) to 7.4 (1.1) min at the masseter and soleus muscles, respectively (Pϭ0.0006). Maximum block produced ranged from 51.2 (11.5)% in the thyroarytenoideus to 99.5 (0.5)% in the masseter (Pϭ0.0417, ANOVA; PϾ0.05, Scheffé's test). Time to recovery of T1 to 50% of baseline varied from 8.9 (2.6) min in the thyroarytenoideus to 20.3 (3.1) min in the masseter (Pϭ0.0001). When T1 had recovered to 50% of baseline, T4/T1 ratios ranged from 0.25 (0.06) in the soleus to 0.56 (0.06) in the masseter muscle (Pϭ 0.0417, ANOVA), and were not significantly different between muscles (PϾ0.05, Scheffé's test). The ED 50 of vecuronium at the six muscles ranged from 7.5 (1.5) to 15.6 (2.5) µg kg -1 at the masseter and thyroarytenoideus muscles, respectively (Pϭ0.1852) ( Table 3 ). The slopes of the dose-response curves were steep, especially in the masseter muscle (i.e. the dose range over which 0-100% block occurred was narrow).
Muscle morphological characteristics
The six muscles differed in morphological variables (Table  4) . Of note, the thyroarytenoideus was composed of fibres with the smallest cross-sectional area (CSA), the largest end-plate surface area (ESA) to fibre CSA ratio (ESA:CSA ratio) and the largest number of AChR per unit fibre CSA. Fibres in the masseter had relatively small CSA, the smallest ESA and a low number of AChR per unit fibre CSA. In addition, fibres in the masseter were histochemically unique in that their mATPase activity at pH 9.4 was not reversed after preincubation at pH 4.3, as was the case in the other muscles. The soleus contained fibres with the largest CSA, least ESA:CSA ratio and least AChR per unit fibre CSA (Table 4) .
Relationships between muscle pharmacodynamic responses
There was a direct correlation between onset time and duration of block (r 2 ϭ0.23; Pϭ0.0015), and an inverse correlation between onset time and the ED 50 of vecuronium (r 2 ϭ0.17; Pϭ0.010). That is, with the exception of the masseter, duration of block was shorter and the ED 50 greater in muscles with short onset times than in muscles with long onset times.
Muscle morphological vs pharmacodynamic characteristics
Simple regression analysis was used to investigate the relationships between ED 50 and duration of block vs each morphological variable. Based on the results, stepwise and multiple regression analyses were performed with ED 50 and duration of action as the dependent variables, and AChR per unit fibre CSA, fibre CSA, ESA:CSA ratio and onset time as the independent variables. Simple regression analysis indicated an inverse relationship between duration of block and number of AChR per unit fibre CSA (r 2 ϭ0.30; Pϭ0.0002). That is, duration of block was greatest in muscles composed of large fibres with relatively small numbers of AChR (Fig. 1) . Duration was also inversely related to ESA (r 2 ϭ0.41; Pϭ0.0001) and ESA:CSA ratio (r 2 ϭ0.23; Pϭ0.0016), and related directly to fibre CSA (r 2 ϭ0.12; Pϭ0.012). There was no association between duration of block and muscle fibre type composition (r 2 ϭ0.05; Pϭ0.149). The ED 50 of vecuronium was related directly to the number of AChR per unit fibre CSA (r 2 ϭ0.24; Pϭ0.0016). That is, the ED 50 of vecuronium was greatest in muscles composed of small calibre fibres with a large number of AChR (Fig. 2) . The ED 50 did not correlate with fibre CSA (r 2 ϭ0.08; Pϭ0.069), fibre type Table 4 Type I fibre composition, mean fibre cross-sectional area (CSA), end-plate surface area (ESA), ESA:fibre CSA ratio, junctional AChR numbers, junctional AChR density and AChR per unit fibre CSA in the thyroarytenoideus (TA), masseter (MAS), diaphragm (DIA), tibialis cranialis (TC), rectus abdominis (RA) and soleus (SOL) muscles in the cat (mean (SEM); nϭ6-7 
Discussion
In this study, the ED 50 and duration of action of the non-depolarizing neuromuscular blocker, vecuronium, were taken as measures of muscle sensitivity in the cat. The main findings were that sensitivity to vecuronium was greatest in muscles composed of fibres with a small number of AChR relative to fibre CSA. Thus sensitivity was least in the thyroarytenoideus (ED 50 15.6 µg kg -1 ; duration 8.9 min) which had the smallest fibres (CSA 799 µm 2 ) with the largest number of AChR per unit fibre CSA (24 000 AChR µm -2 ). The most sensitive muscle (ED 50 7.5 µg kg -1 ; duration 20.3 min) was the masseter which had a low number of AChR per unit fibre CSA (8700 AChR µm -2 ). Indeed, the number of AChR per unit fibre CSA in the masseter may have been overestimated because fibres with end-plates that were too small or ill-defined were excluded. Duration of block (13.8-19.1 min) and ED 50 (11.9-13.6 µg kg -1 ) of vecuronium in the limb and abdominal muscles were also consistent with their larger fibre CSA (2658-4238 µm 2 ) which more than compensated for the number of AChR (16.6-34.6ϫ10 6 ), reducing the number of AChR per unit fibre CSA to 4100-14 600 AChR µm -2 . We also showed that, in the cat, duration of block correlated directly with fibre CSA and inversely with end-plate size relative to fibre CSA, consistent with previous reports in the goat in which species AChR density was relatively constant across muscles so that end-plate size was a good measure of the number of AChR per end-plate.
When comparing our results with previous findings in the goat, 1 4 it is important to consider the differences in the methods used. We used a 'repeated bolus dose-response' method in contrast with the single bolus or cumulative dose-response method in the goat studies. 1 4 Also, our dose-response study was carried out in two phases to obtain data on onset, intensity and duration of action of vecuronium in six muscles using a minimum number of cats and the four-channel polygraph available. This experimental design has the inherent limitation that if adequate intervals are not allowed between doses, residual block from preceding doses can exaggerate sensitivity to subsequent doses. Indeed, the ED 50 of vecuronium was smaller during the second than during the first phase in the tibialis, but not in the soleus muscle, suggesting some degree of drug cumulation in the tibialis (Table 1) . It is not clear if the finding in the tibialis was coincidental, or to what extent drug cumulation affected the other muscles. None the less, duration of block and ED 50 of vecuronium in each muscle were normalized to those in the tibialis muscle in the same cat and phase, and the normalized values used for comparisons between muscles. Although this data manipulation was used primarily to correct for the variability in response between animals to allow demonstration of differences in response between muscles using a minimum number of cats, it could also have corrected for drug cumulation in the other muscles. However, it must be emphasized that the validity of the conclusions in this study rest on the assumption that cumulation was not markedly greater in the other muscles than in the tibialis muscle. As the latter was not verified specifically and cannot be ruled out completely, the issue of drug cumulation, an inherent limitation of the present experimental study, must be borne in mind in interpreting our findings.
Despite these limitations, we have confirmed previous experimental 1 7 12 13 and clinical [14] [15] [16] [17] reports that onset of non-depolarizing neuromuscular block is faster in the diaphragm, laryngeal and masseter muscles than in limb muscles. The potency of vecuronium, as reflected by the ED 50 , was greatest in the masseter and least in the thyroarytenoideus (PϾ0.05). These results appear consistent with the differences in circulation time and perfusion between muscles. 18 19 The diaphragm, masseter and laryngeal muscles are proximal to the heart and better perfused 20 21 so that they receive the injected drug earlier and in larger amounts than the more distant, less perfused limb muscles. Earlier drug delivery results in a shorter onset time, while the greater amount of drug delivered results in greater block in the masseter but not in the diaphragm or thyroarytenoideus muscles because the latter two are more resistant to neuromuscular blocking drugs than limb muscles. Thus the ED 50 might mask the differential sensitivities between muscles. 16 Also, the present and previous 1 4 studies contradict previous reports that the unequal intensities of block may be related to differences in fibre type composition between muscles. 22 23 As regards duration of block, it has been suggested that recovery from neuromuscular block may be related to the rate of dissociation of the blocker drug-receptor complex. 24 However, this is unlikely as the affinity of 289 AChR for neuromuscular blocking drugs does not differ between muscles, 25 and the association and dissociation of blocker drug molecules with AChR occur within milliseconds whereas onset and offset of block take minutes. 26 Another hypothesis is that the rate of recovery from block is limited by 'tissue factors', such as the density of junctional AChR 27 or binding of the drug to mucopolysaccharides of the basement membrane 28 that 'restrict' or 'buffer' drug diffusion through the synaptic cleft. If so, these 'tissue factors' should influence onset and offset of block alike. While the direct associations between onset time and duration of vecuronium block in the cat (present study) and of four neuromuscular blocking drugs in humans 29 appear to support this hypothesis, it is possible that these associations are merely coincidental rather than causal as duration was long in the masseter despite a short onset time.
Our findings support our hypothesis that the differential responses of muscles to neuromuscular blocking drugs are related to the number of AChR per unit fibre CSA. This in turn would suggest that the responses of muscles to neuromuscular blocking drugs may be related to the amplitude of the end-plate potential. Each activated AChR allows a fixed current (I) to go through during a fixed open time (t), such that the total charge (QϭIϫtϫn) transferred is proportional to the number of open AChR channels. The end-plate potential (V) equals the total charge transferred divided by the capacitance (C) of the fibre (VϭQ/C). Capacitance is related directly to fibre CSA. 3 Hence the number of AChR per unit fibre CSA should be proportional to the amplitude of the end-plate potential. A large number of AChR and/or small capacitance (fibre size) enhance the probability that the end-plate potential exceeds the action potential threshold resulting in muscle contraction and recovery from block. Thus the number of AChR per unit fibre CSA may be a morphological predictor of the differential responses of muscles to neuromuscular blocking drugs. However, this hypothesis and the relatively weak correlation coefficients found in this study also imply that other factors play a role in regulating the differential sensitivities of muscles to neuromuscular blocking drugs. These factors may include the size and number of quanta of acetylcholine released from the nerve terminal, level of acetylcholinesterase activity in the synaptic cleft and blood flow to various muscles. These factors deserve further investigation.
Our hypothesis may explain the differential responses to neuromuscular blocking drugs, not only between muscles within individuals, but also between different mammalian species. For example, the lower ED 50 of vecuronium in the goat (2.8-3.7 mg kg -1 ) than in the cat (10.3-15.6 mg kg -1 ) would be consistent with both the lower number of AChR per end-plate (6.6-14.5ϫ10 6 AChR vs 14.3-35.0ϫ10 6 AChR) and the lower number of AChR per unit fibre CSA (3.9-14.2ϫ10 3 AChR µm -2 vs 4.0-24.0ϫ10 3 AChR µm -2 ) for corresponding muscles in the goat and cat, respectively. Similarly, this hypothesis may explain the changes in response to neuromuscular blocking drugs in various pathophysiological states. Using this hypothesis, conditions that produce an increase in the number of junctional AChR or a decrease in fibre size, or both, such that the number of AChR per unit fibre CSA increases, should produce resistance to non-depolarizing neuromuscular blocking drugs. This would explain the resistance to non-depolarizing neuromuscular blocking drugs after denervation, for example. Conversely, conditions that produce down-regulation of junctional AChR or fibre hypertrophy, or both, resulting in a decline in the number of AChR per unit fibre CSA, would increase sensitivity to nondepolarizing neuromuscular blocking drugs. Myasthenia gravis may represent this scenario. However, if the change in junctional AChR number were associated with a corresponding change in fibre CSA so that the number of AChR per unit fibre CSA remained unchanged, then sensitivity would remain unchanged. The plethora of possible scenarios may explain the discrepancies in the reported responses of muscles to neuromuscular blocking drugs in various conditions (see Martyn and colleagues 30 for review). Fortunately, they also make the hypothesis more amenable to verification. 31 In summary, we have demonstrated that duration of action, but not ED 50 , of vecuronium in six muscles in the cat correlated directly with fibre size and inversely with relative end-plate size, findings remarkably similar to those in the goat. 1 4 These suggest that a similar mechanism(s) may explain the differential responses of muscles to neuromuscular blocking drugs in goats and cats, and possibly other mammalian species. Duration of vecuronium block was related inversely while ED 50 of vecuronium was related directly to the number of AChR per unit fibre CSA, thus indicating that the number of AChR per unit fibre CSA is a morphological predictor of muscle response to neuromuscular blocking drugs. 
